Douglas E. Williams

Douglas E. Williams, PhD, is Head of Research and Development at Sana Biotechnology.

Prior to joining Sana, Douglas served as the President and CEO of Codiak BioSciences. From January 2011 to July 2015, he served as the Executive Vice President of Research and Development at Biogen. He joined Biogen from ZymoGenetics, where he was most recently CEO and member of the board of directors. ZymoGenetics was acquired by Bristol-Myers Squibb during his tenure.

Prior to ZymoGenetics, Douglas held various leadership positions within the biotechnology industry, including Chief Scientific Officer and Executive Vice President of Research and Development at Seagen (formerly Seattle Genetics), and Senior Vice President and Washington Site Leader at Amgen. Douglas served in a series of scientific and senior leadership positions over a decade at Immunex, including Executive Vice President and Chief Technology Officer, and as a member of its board of directors. During his biotechnology career spanning over 30 years, he has played a role in the development of several novel drugs, including Enbrel®, Tecfidera®, and Spinraza®. He has served on the boards of directors of numerous biotechnology companies and currently serves as Chairman of the Board of AC Immune and on the boards of directors of Panacea II and Codiak, as well as the private company Stablix.

Douglas obtained an A.A. from Greenfield Community College, a B.S. from the University of Massachusetts Lowell, and a PhD from the State University of New York at Buffalo.